Daiichi Sankyo Unit Seeks $178M From Novartis As Trial Ends

Law360 (July 21, 2021, 9:27 PM EDT) -- Daiichi Sankyo subsidiary's counsel told a California federal jury during trial closings Wednesday that Novartis owes more than $177.8 million in royalties and fixed payments for infringing its skin cancer treatment patents, while Novartis' attorney argued that the patents are invalid and should never have been issued.

The attorneys' arguments wrapped an in-person jury trial that kicked off July 12 over Plexxikon Inc.'s claims that Novartis owes royalties for selling a skin cancer drug called Tafinlar that Plexxikon says infringes two of its patents.

The patents-in-suit cover molecular compounds that use the same mechanism of action as Plexxikon's rival cancer treatment...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!